Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

Phase 2positiveDISC-3405selcodebartPositive

AI Analysis

Summary

Disc Medicine announced positive Phase 2 RESTORE-PV trial results for DISC-3405 in polycythemia vera patients, showing increased hepcidin, reduced serum iron, and improved clinical outcomes. The company also presented data from the RALLY-MF Phase 2 trial of selcodebart in myelofibrosis-associated anemia at the SOHO annual meeting.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

DISC-3405 increased hepcidin and lowered serum iron, resulting in reduction in phlebotomy, controlled hematocrit, and improved symptom burden in PV patients

Importance:7/10

Sentiment:

0.75

Phase 2 dataHematologic diseasesConference presentationSOHO 2026

Related Companies

$IRON

Read the original article

Published by GlobeNewswire Clinical Studies on September 9, 2026 11:25 PM

Read Original